Evaluating strategies for the treatment of cerebral cavernous malformations
- PMID: 20876517
- PMCID: PMC3409848
- DOI: 10.1161/STROKEAHA.110.594929
Evaluating strategies for the treatment of cerebral cavernous malformations
Abstract
Cerebral cavernous malformations are common vascular lesions of the central nervous system that predispose to seizures, focal neurological deficits, and potentially fatal hemorrhagic stroke. Human genetic studies have identified 3 genes associated with the disease, and biochemical studies of these proteins have identified interaction partners and possible signaling pathways. A recurring theme dominating the recent scientific literature is the causal link between mutations in the 3 cerebral cavernous malformation genes and hyperactivation of the small GTP exchange protein, RhoA, and the efficacy of reducing this hyperactivation using inexpensive and well-studied medicines, statins. Familial cerebral cavernous malformation offers a unique opportunity to use a personalized genomic medicine approach to identify a subset of patients prone to intracerebral hemorrhage that may benefit from a pharmacological therapy, where presently only neurosurgical options are available.
Comment in
-
Letter by Filippidis et al regarding article, "Evaluating strategies for the treatment of cerebral cavernous malformations".Stroke. 2011 May;42(5):e373. doi: 10.1161/STROKEAHA.110.606251. Epub 2011 Mar 10. Stroke. 2011. PMID: 21393598 No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources